Sign up to save your podcasts
Or
Share Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL
Dr. Patel, of the Swedish Cancer Institute in Seattle, Washington, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss novel frontline therapies in the lymphoma space, including the bispecific antibody glofitamab.
They also discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy, fixed duration therapy and step-up dosing, and how to sequence therapy.
View all episodes
By Rahul Banerjee, MD
4.8
2727 ratings
Dr. Patel, of the Swedish Cancer Institute in Seattle, Washington, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss novel frontline therapies in the lymphoma space, including the bispecific antibody glofitamab.
They also discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy, fixed duration therapy and step-up dosing, and how to sequence therapy.